CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Adalimumab

Adalimumab

Last Updated: February 4, 2013

Result type: Reports

Project Number: SR0308-000

Product Line: Reimbursement Review

Generic Name: Adalimumab

Brand Name: Humira

Manufacturer: AbbVie Corporation

Therapeutic Area: Arthritis, juvenile idiopathic

Indications: Arthritis, Juvenile Idiopathic

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 18, 2013

Recommendation Type: List with clinical criteria and/or conditions

Adalimumab

Files